In September 2021, a Novel Excipient Review Pilot Program was launched in the US that would allow excipient manufacturers to get their novel excipient approved for use in pharmaceuticals prior to use. In this roundtable, five experts from IPEC-Americas give their view on this why this is so important – and how it could transform the industry.
This is a lengthy discussion so grab a coffee and get comfy!
Or you can read an abridged version of the discussion here.
Featuring:
- Kathy Ulman, President and owner of KLU Consulting, and Vice Chair of the Regulatory Affairs Committee at IPEC-Americas
- Priscilla Zawislak, Global Regulatory Affairs Advocacy Manager at International Flavours and Fragrances (IFF), and the Immediate Past Chair of IPEC-Americas
- Meera Raghuram, Director for Regulatory and Sustainability at Lubrizol, and Chair of IPEC-America’s Regulatory Affairs Committee
- Dave Schoneker, President and owner of Black Diamond Regulatory Consulting, and one of the original founders of IPEC-Americas.
- Nigel Langley, Global Technology Director for BASF and current Chair of IPEC-Americas
Kathy Ulman, President and owner of KLU Consulting, and Vice Chair of the Regulatory Affairs Committee at IPEC-Americas
Nigel Langley, Global Technology Director for BASF and current Chair of IPEC-Americas
Meera Raghuram, Director for Regulatory and Sustainability at Lubrizol, and Chair of IPEC-America’s Regulatory Affairs Committee
Dave Schoneker, President and owner of Black Diamond Regulatory Consulting, and one of the original founders of IPEC-Americas.
Priscilla Zawislak, Global Regulatory Affairs Advocacy Manager at International Flavours and Fragrances (IFF), and the Immediate Past Chair of IPEC-Americas
Newsletters
Receive the latest analytical science news, personalities, education, and career development – weekly to your inbox.
